Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome

Nature

Volumn 448, Issue 7157, 2007, Pages 1058-1062

  Minegishi, Yoshiyuki ^a   Saito, Masako ^a   Tsuchiya, Shigeru ^b   Tsuge, Ikuya ^c   Takada, Hidetoshi ^d   Hara, Toshiro ^d   Kawamura, Nobuaki ^e   Ariga, Tadashi ^e   Pasic, Srdjan ^f   Stojkovic, Oliver ^g   Metin, Ayse ^h   Karasuyama, Hajime ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c FUJITA HEALTH UNIVERSITY   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

^e HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f Mother and Child Health Institute Belgrade rs   (Serbia)

^g UNIVERSITY OF BELGRADE   (Serbia)

^h SB Ankara Diskapi Training and Research Hospital   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; IMMUNOGLOBULIN E; INTERLEUKIN 10; INTERLEUKIN 6; STAT3 PROTEIN;

CYST; DNA; DOMINANCE; MUTATION; PNEUMONIA;

ALLELE; ARTICLE; BLOOD CELL; CYTOKINE RELEASE; DNA BINDING; GENE MUTATION; GENETIC TRANSCRIPTION; HETEROZYGOSITY; HUMAN; HUMAN CELL; HYPERIMMUNOGLOBULINEMIA E; NUCLEOTIDE SEQUENCE; PARENT; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; SIBLING; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; WILD TYPE;

EID: 34548317417     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature06096     Document Type: Article

References (30)

1. Grimbacher, B., Holland, S. M. & Puck, J. M. Hyper-IgE syndromes. Immunol. Rev. 203, 244-250 (2005).
2. Gould, H. J. et al. The biology of IGE and the basis of allergic disease. Annu. Rev. Immunol. 21, 579-628 (2003).
3. Grimbacher, B., Belohradsky, B. H. & Holland, S. M. Immunoglobulin E in primary immunodeficiency diseases. Allergy 57, 995-1007 (2002).
4. Davis, S. D., Schaller, J. & Wedgwood, R. J. Job's Syndrome. Recurrent, "cold", staphylococcal abscesses. Lancet 1, 1013-1015 (1966).
5. Buckley, R. H., Wray, B. B. & Belmaker, E. Z. Extreme hyperimmunoglobulinemia E and undue susceptibility to infection. Pediatrics 49, 59-70 (1972).
6. Grimbacher, B. et al. Hyper-IgE syndrome with recurrent infections - an autosomal dominant multisystem disorder. N. Engl. J. Med. 340, 692-702 (1999).
7. Renner, E. D. et al. Autosomal recessive hyperimmunoglobulin E syndrome: a distinct disease entity. J. Pediatr. 144, 93-99 (2004).
8. Minegishi, Y. et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 25, 745-755 (2006).
9. Schindler, C. & Darnell, J. E. Jr. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu. Rev. Biochem. 64, 621-651 (1995).
10. Ihle, J. N. Cytokine receptor signalling. Nature 377, 591-594 (1995).
11. Levy, D. E. & Darnell, J. E. Jr. STATs: transcriptional control and biological impact. Nature Rev. Mol. Cell Biol. 3, 651-662 (2002).
12. Kisseleva, T., Bhattacharya, S., Braunstein, J. & Schindler, C. W. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 285, 1-24 (2002).
13. Grimbacher, B. et al. Genetic linkage of hyper-IgE syndrome to chromosome 4. Am. J. Hum. Genet. 65, 735-744 (1999).
14. Horvath, C. M., Wen, Z. & Darnell, J. E. Jr. A STAT protein domain that determines DNA sequence recognition suggests a novel DNA-binding domain. Genes Dev. 9, 984-994 (1995).
15. Chapgier, A. et al. Novel STAT1 alleles in otherwise healthy patients with mycobacterial disease. PLoS Genet. 2, e131 (2006).
16. Takeda, K. et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc. Natl Acad. Sci. USA 94, 3801-3804 (1997).
17. Darnell, J. E. Jr. STATs and gene regulation. Science 277, 1630-1635 (1997).
18. Levy, D. E. & Lee, C. K. What does Stat3 do? J. Clin. Invest. 109, 1143-1148 (2002).
19. O'Brien, C. A., Gubrij, I., Lin, S. C., Saylors, R. L. & Manolagas, S. C. STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-κB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroid hormone. J. Biol. Chem. 274, 19301-19308 (1999).
20. Itoh, S. et al. A critical role for interleukin-6 family-mediated Stat3 activation in osteoblast differentiation and bone formation. Bone 39, 505-512 (2006).
21. Akira, S. et al. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 77, 63-71 (1994).
22. Zhong, Z., Wen, Z. & Darnell, J. E. Jr. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264, 95-98 (1994).
23. Li, W., Liang, X., Kellendonk, C., Poli, V. & Taub, R. STAT3 contributes to the mitogenic response of hepatocytes during liver regeneration. J. Biol. Chem. 277, 28411-28417 (2002).
24. Robinson, D. S., Larche, M. & Durham, S. R. Tregs and allergic disease. J. Clin. Invest. 114, 1389-1397 (2004).
25. Yang, X. O. et al. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J. Biol. Chem. 282, 9358-9363 (2007).
26. Happel, K. I. et al. Divergent roles of IL-23 and IL-12 in host defense against Klebsiella pneumoniae. J. Exp. Med. 202, 761-769 (2005).
27. Wolk, K. et al. IL-22 increases the innate immunity of tissues. Immunity 21, 241-254 (2004).
28. Minegishi, Y. & Conley, M. E. Negative selection at the pre-BCR checkpoint elicited by human μ heavy chains with unusual CDR3 regions. Immunity 14, 631-641 (2001).
29. Minegishi, Y. et al. Mutations in Igα (CD79a) result in a complete block in B-cell development. J. Clin. Invest. 104, 1115-1121 (1999).
30. Minegishi, Y. et al. An essential role for BLNK in human B cell development. Science 286, 1954-1957 (1999).